Pharma & Healthcare
Global Biologics for Severe Asthma Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 570829
- Pages: 141
- Figures: 137
- Views: 32
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Biologics for Severe Asthma market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
AstraZeneca
Amgen
Roche
Novartis
Sanofi
Regeneron Pharmaceuticals
GSK
Teva Pharmaceuticals
Segment by Type
Omalizumab
Benralizumab
Dupirumab
Mepolizumab
Reslizumab
Tezepelumab-ekko
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Biologics for Severe Asthma study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Biologics for Severe Asthma market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
AstraZeneca
Amgen
Roche
Novartis
Sanofi
Regeneron Pharmaceuticals
GSK
Teva Pharmaceuticals
Segment by Type
Omalizumab
Benralizumab
Dupirumab
Mepolizumab
Reslizumab
Tezepelumab-ekko
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Biologics for Severe Asthma study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Biologics for Severe Asthma: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Biologics for Severe Asthma Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Omalizumab
1.2.3 Benralizumab
1.2.4 Dupirumab
1.2.5 Mepolizumab
1.2.6 Reslizumab
1.2.7 Tezepelumab-ekko
1.3 Market Segmentation by Application
1.3.1 Global Biologics for Severe Asthma Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Biologics for Severe Asthma Revenue Estimates and Forecasts 2020-2031
2.2 Global Biologics for Severe Asthma Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Biologics for Severe Asthma Sales Estimates and Forecasts 2020-2031
2.4 Global Biologics for Severe Asthma Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Biologics for Severe Asthma Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Biologics for Severe Asthma Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Omalizumab Market Size by Manufacturers
3.5.2 Benralizumab Market Size by Manufacturers
3.5.3 Dupirumab Market Size by Manufacturers
3.5.4 Mepolizumab Market Size by Manufacturers
3.5.5 Reslizumab Market Size by Manufacturers
3.5.6 Tezepelumab-ekko Market Size by Manufacturers
3.6 Global Biologics for Severe Asthma Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Biologics for Severe Asthma Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Biologics for Severe Asthma Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Biologics for Severe Asthma Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Biologics for Severe Asthma Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Biologics for Severe Asthma Sales and Revenue by Type (2020-2031)
6.4 North America Biologics for Severe Asthma Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Biologics for Severe Asthma Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Biologics for Severe Asthma Sales and Revenue by Type (2020-2031)
7.4 Europe Biologics for Severe Asthma Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Biologics for Severe Asthma Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Biologics for Severe Asthma Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Biologics for Severe Asthma Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Biologics for Severe Asthma Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Biologics for Severe Asthma Sales and Revenue by Type (2020-2031)
9.4 Central and South America Biologics for Severe Asthma Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Biologics for Severe Asthma Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Biologics for Severe Asthma Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Biologics for Severe Asthma Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Biologics for Severe Asthma Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.1.4 AstraZeneca Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 AstraZeneca Biologics for Severe Asthma Sales by Product in 2024
11.1.6 AstraZeneca Biologics for Severe Asthma Sales by Application in 2024
11.1.7 AstraZeneca Biologics for Severe Asthma Sales by Geographic Area in 2024
11.1.8 AstraZeneca Biologics for Severe Asthma SWOT Analysis
11.1.9 AstraZeneca Recent Developments
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Business Overview
11.2.3 Amgen Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.2.4 Amgen Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Amgen Biologics for Severe Asthma Sales by Product in 2024
11.2.6 Amgen Biologics for Severe Asthma Sales by Application in 2024
11.2.7 Amgen Biologics for Severe Asthma Sales by Geographic Area in 2024
11.2.8 Amgen Biologics for Severe Asthma SWOT Analysis
11.2.9 Amgen Recent Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Business Overview
11.3.3 Roche Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.3.4 Roche Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Roche Biologics for Severe Asthma Sales by Product in 2024
11.3.6 Roche Biologics for Severe Asthma Sales by Application in 2024
11.3.7 Roche Biologics for Severe Asthma Sales by Geographic Area in 2024
11.3.8 Roche Biologics for Severe Asthma SWOT Analysis
11.3.9 Roche Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview
11.4.3 Novartis Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.4.4 Novartis Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Novartis Biologics for Severe Asthma Sales by Product in 2024
11.4.6 Novartis Biologics for Severe Asthma Sales by Application in 2024
11.4.7 Novartis Biologics for Severe Asthma Sales by Geographic Area in 2024
11.4.8 Novartis Biologics for Severe Asthma SWOT Analysis
11.4.9 Novartis Recent Developments
11.5 Sanofi
11.5.1 Sanofi Corporation Information
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.5.4 Sanofi Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Sanofi Biologics for Severe Asthma Sales by Product in 2024
11.5.6 Sanofi Biologics for Severe Asthma Sales by Application in 2024
11.5.7 Sanofi Biologics for Severe Asthma Sales by Geographic Area in 2024
11.5.8 Sanofi Biologics for Severe Asthma SWOT Analysis
11.5.9 Sanofi Recent Developments
11.6 Regeneron Pharmaceuticals
11.6.1 Regeneron Pharmaceuticals Corporation Information
11.6.2 Regeneron Pharmaceuticals Business Overview
11.6.3 Regeneron Pharmaceuticals Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.6.4 Regeneron Pharmaceuticals Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Regeneron Pharmaceuticals Recent Developments
11.7 GSK
11.7.1 GSK Corporation Information
11.7.2 GSK Business Overview
11.7.3 GSK Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.7.4 GSK Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 GSK Recent Developments
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Corporation Information
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.8.4 Teva Pharmaceuticals Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Teva Pharmaceuticals Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Biologics for Severe Asthma Industry Chain
12.2 Biologics for Severe Asthma Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Biologics for Severe Asthma Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Biologics for Severe Asthma Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Biologics for Severe Asthma Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Biologics for Severe Asthma Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Biologics for Severe Asthma: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Biologics for Severe Asthma Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Omalizumab
1.2.3 Benralizumab
1.2.4 Dupirumab
1.2.5 Mepolizumab
1.2.6 Reslizumab
1.2.7 Tezepelumab-ekko
1.3 Market Segmentation by Application
1.3.1 Global Biologics for Severe Asthma Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Biologics for Severe Asthma Revenue Estimates and Forecasts 2020-2031
2.2 Global Biologics for Severe Asthma Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Biologics for Severe Asthma Sales Estimates and Forecasts 2020-2031
2.4 Global Biologics for Severe Asthma Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Biologics for Severe Asthma Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Biologics for Severe Asthma Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Omalizumab Market Size by Manufacturers
3.5.2 Benralizumab Market Size by Manufacturers
3.5.3 Dupirumab Market Size by Manufacturers
3.5.4 Mepolizumab Market Size by Manufacturers
3.5.5 Reslizumab Market Size by Manufacturers
3.5.6 Tezepelumab-ekko Market Size by Manufacturers
3.6 Global Biologics for Severe Asthma Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Biologics for Severe Asthma Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Biologics for Severe Asthma Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Biologics for Severe Asthma Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Biologics for Severe Asthma Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Biologics for Severe Asthma Sales and Revenue by Type (2020-2031)
6.4 North America Biologics for Severe Asthma Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Biologics for Severe Asthma Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Biologics for Severe Asthma Sales and Revenue by Type (2020-2031)
7.4 Europe Biologics for Severe Asthma Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Biologics for Severe Asthma Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Biologics for Severe Asthma Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Biologics for Severe Asthma Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Biologics for Severe Asthma Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Biologics for Severe Asthma Sales and Revenue by Type (2020-2031)
9.4 Central and South America Biologics for Severe Asthma Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Biologics for Severe Asthma Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Biologics for Severe Asthma Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Biologics for Severe Asthma Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Biologics for Severe Asthma Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.1.4 AstraZeneca Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 AstraZeneca Biologics for Severe Asthma Sales by Product in 2024
11.1.6 AstraZeneca Biologics for Severe Asthma Sales by Application in 2024
11.1.7 AstraZeneca Biologics for Severe Asthma Sales by Geographic Area in 2024
11.1.8 AstraZeneca Biologics for Severe Asthma SWOT Analysis
11.1.9 AstraZeneca Recent Developments
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Business Overview
11.2.3 Amgen Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.2.4 Amgen Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Amgen Biologics for Severe Asthma Sales by Product in 2024
11.2.6 Amgen Biologics for Severe Asthma Sales by Application in 2024
11.2.7 Amgen Biologics for Severe Asthma Sales by Geographic Area in 2024
11.2.8 Amgen Biologics for Severe Asthma SWOT Analysis
11.2.9 Amgen Recent Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Business Overview
11.3.3 Roche Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.3.4 Roche Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Roche Biologics for Severe Asthma Sales by Product in 2024
11.3.6 Roche Biologics for Severe Asthma Sales by Application in 2024
11.3.7 Roche Biologics for Severe Asthma Sales by Geographic Area in 2024
11.3.8 Roche Biologics for Severe Asthma SWOT Analysis
11.3.9 Roche Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview
11.4.3 Novartis Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.4.4 Novartis Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Novartis Biologics for Severe Asthma Sales by Product in 2024
11.4.6 Novartis Biologics for Severe Asthma Sales by Application in 2024
11.4.7 Novartis Biologics for Severe Asthma Sales by Geographic Area in 2024
11.4.8 Novartis Biologics for Severe Asthma SWOT Analysis
11.4.9 Novartis Recent Developments
11.5 Sanofi
11.5.1 Sanofi Corporation Information
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.5.4 Sanofi Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Sanofi Biologics for Severe Asthma Sales by Product in 2024
11.5.6 Sanofi Biologics for Severe Asthma Sales by Application in 2024
11.5.7 Sanofi Biologics for Severe Asthma Sales by Geographic Area in 2024
11.5.8 Sanofi Biologics for Severe Asthma SWOT Analysis
11.5.9 Sanofi Recent Developments
11.6 Regeneron Pharmaceuticals
11.6.1 Regeneron Pharmaceuticals Corporation Information
11.6.2 Regeneron Pharmaceuticals Business Overview
11.6.3 Regeneron Pharmaceuticals Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.6.4 Regeneron Pharmaceuticals Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Regeneron Pharmaceuticals Recent Developments
11.7 GSK
11.7.1 GSK Corporation Information
11.7.2 GSK Business Overview
11.7.3 GSK Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.7.4 GSK Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 GSK Recent Developments
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Corporation Information
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Biologics for Severe Asthma Product Models, Descriptions and Specifications
11.8.4 Teva Pharmaceuticals Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Teva Pharmaceuticals Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Biologics for Severe Asthma Industry Chain
12.2 Biologics for Severe Asthma Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Biologics for Severe Asthma Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Biologics for Severe Asthma Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Biologics for Severe Asthma Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Biologics for Severe Asthma Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Biologics for Severe Asthma Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Biologics for Severe Asthma Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Biologics for Severe Asthma Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Biologics for Severe Asthma Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Biologics for Severe Asthma Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Biologics for Severe Asthma Sales by Region (2020-2025) & (K Units)
Table 8. Global Biologics for Severe Asthma Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Biologics for Severe Asthma Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Biologics for Severe Asthma Sales Share by Manufacturers (2020-2025)
Table 12. Global Biologics for Severe Asthma Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Biologics for Severe Asthma Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Biologics for Severe Asthma by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics for Severe Asthma as of 2024)
Table 16. Global Biologics for Severe Asthma Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Biologics for Severe Asthma Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Biologics for Severe Asthma Manufacturing Base and Headquarters
Table 19. Global Biologics for Severe Asthma Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Biologics for Severe Asthma Sales by Type (2020-2025) & (K Units)
Table 23. Global Biologics for Severe Asthma Sales by Type (2026-2031) & (K Units)
Table 24. Global Biologics for Severe Asthma Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Biologics for Severe Asthma Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Biologics for Severe Asthma ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Biologics for Severe Asthma Sales by Application (2020-2025) & (K Units)
Table 29. Global Biologics for Severe Asthma Sales by Application (2026-2031) & (K Units)
Table 30. Biologics for Severe Asthma High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Biologics for Severe Asthma Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Biologics for Severe Asthma Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Biologics for Severe Asthma ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Biologics for Severe Asthma Growth Accelerators and Market Barriers
Table 37. North America Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Biologics for Severe Asthma Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Biologics for Severe Asthma Growth Accelerators and Market Barriers
Table 40. Europe Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Biologics for Severe Asthma Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Biologics for Severe Asthma Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Biologics for Severe Asthma Growth Accelerators and Market Barriers
Table 45. Southeast Asia Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Biologics for Severe Asthma Investment Opportunities and Key Challenges
Table 47. Central and South America Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Biologics for Severe Asthma Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. AstraZeneca Corporation Information
Table 51. AstraZeneca Description and Major Businesses
Table 52. AstraZeneca Product Models, Descriptions and Specifications
Table 53. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. AstraZeneca Sales Value Proportion by Product in 2024
Table 55. AstraZeneca Sales Value Proportion by Application in 2024
Table 56. AstraZeneca Sales Value Proportion by Geographic Area in 2024
Table 57. AstraZeneca Biologics for Severe Asthma SWOT Analysis
Table 58. AstraZeneca Recent Developments
Table 59. Amgen Corporation Information
Table 60. Amgen Description and Major Businesses
Table 61. Amgen Product Models, Descriptions and Specifications
Table 62. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Amgen Sales Value Proportion by Product in 2024
Table 64. Amgen Sales Value Proportion by Application in 2024
Table 65. Amgen Sales Value Proportion by Geographic Area in 2024
Table 66. Amgen Biologics for Severe Asthma SWOT Analysis
Table 67. Amgen Recent Developments
Table 68. Roche Corporation Information
Table 69. Roche Description and Major Businesses
Table 70. Roche Product Models, Descriptions and Specifications
Table 71. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Roche Sales Value Proportion by Product in 2024
Table 73. Roche Sales Value Proportion by Application in 2024
Table 74. Roche Sales Value Proportion by Geographic Area in 2024
Table 75. Roche Biologics for Severe Asthma SWOT Analysis
Table 76. Roche Recent Developments
Table 77. Novartis Corporation Information
Table 78. Novartis Description and Major Businesses
Table 79. Novartis Product Models, Descriptions and Specifications
Table 80. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Novartis Sales Value Proportion by Product in 2024
Table 82. Novartis Sales Value Proportion by Application in 2024
Table 83. Novartis Sales Value Proportion by Geographic Area in 2024
Table 84. Novartis Biologics for Severe Asthma SWOT Analysis
Table 85. Novartis Recent Developments
Table 86. Sanofi Corporation Information
Table 87. Sanofi Description and Major Businesses
Table 88. Sanofi Product Models, Descriptions and Specifications
Table 89. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Sanofi Sales Value Proportion by Product in 2024
Table 91. Sanofi Sales Value Proportion by Application in 2024
Table 92. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 93. Sanofi Biologics for Severe Asthma SWOT Analysis
Table 94. Sanofi Recent Developments
Table 95. Regeneron Pharmaceuticals Corporation Information
Table 96. Regeneron Pharmaceuticals Description and Major Businesses
Table 97. Regeneron Pharmaceuticals Product Models, Descriptions and Specifications
Table 98. Regeneron Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Regeneron Pharmaceuticals Recent Developments
Table 100. GSK Corporation Information
Table 101. GSK Description and Major Businesses
Table 102. GSK Product Models, Descriptions and Specifications
Table 103. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. GSK Recent Developments
Table 105. Teva Pharmaceuticals Corporation Information
Table 106. Teva Pharmaceuticals Description and Major Businesses
Table 107. Teva Pharmaceuticals Product Models, Descriptions and Specifications
Table 108. Teva Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Teva Pharmaceuticals Recent Developments
Table 110. Key Raw Materials Distribution
Table 111. Raw Materials Key Suppliers
Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 113. Milestones in Production Technology Evolution
Table 114. Distributors List
Table 115. Market Trends and Market Evolution
Table 116. Market Drivers and Opportunities
Table 117. Market Challenges, Risks, and Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Biologics for Severe Asthma Product Picture
Figure 2. Global Biologics for Severe Asthma Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Omalizumab Product Picture
Figure 4. Benralizumab Product Picture
Figure 5. Dupirumab Product Picture
Figure 6. Mepolizumab Product Picture
Figure 7. Reslizumab Product Picture
Figure 8. Tezepelumab-ekko Product Picture
Figure 9. Global Biologics for Severe Asthma Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Other
Figure 13. Biologics for Severe Asthma Report Years Considered
Figure 14. Global Biologics for Severe Asthma Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 16. Global Biologics for Severe Asthma Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Biologics for Severe Asthma Revenue Market Share by Region (2020-2031)
Figure 18. Global Biologics for Severe Asthma Sales (2020-2031) & (K Units)
Figure 19. Global Biologics for Severe Asthma Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Biologics for Severe Asthma Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Biologics for Severe Asthma Sales Volume Market Share in 2024
Figure 22. Global Biologics for Severe Asthma Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Omalizumab Revenue Market Share by Manufacturer in 2024
Figure 25. Benralizumab Revenue Market Share by Manufacturer in 2024
Figure 26. Dupirumab Revenue Market Share by Manufacturer in 2024
Figure 27. Mepolizumab Revenue Market Share by Manufacturer in 2024
Figure 28. Reslizumab Revenue Market Share by Manufacturer in 2024
Figure 29. Tezepelumab-ekko Revenue Market Share by Manufacturer in 2024
Figure 30. Global Biologics for Severe Asthma Sales Market Share by Type (2020-2031)
Figure 31. Global Biologics for Severe Asthma Revenue Market Share by Type (2020-2031)
Figure 32. Global Biologics for Severe Asthma Sales Market Share by Application (2020-2031)
Figure 33. Global Biologics for Severe Asthma Revenue Market Share by Application (2020-2031)
Figure 34. North America Biologics for Severe Asthma Sales YoY (2020-2031) & (K Units)
Figure 35. North America Biologics for Severe Asthma Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Biologics for Severe Asthma Sales Revenue (US$ Million) in 2024
Figure 37. North America Biologics for Severe Asthma Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Biologics for Severe Asthma Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Biologics for Severe Asthma Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Biologics for Severe Asthma Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Biologics for Severe Asthma Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Biologics for Severe Asthma Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Biologics for Severe Asthma Sales Revenue (US$ Million) in 2024
Figure 47. Europe Biologics for Severe Asthma Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Biologics for Severe Asthma Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Biologics for Severe Asthma Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Biologics for Severe Asthma Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 52. France Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Biologics for Severe Asthma Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Biologics for Severe Asthma Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Biologics for Severe Asthma Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Biologics for Severe Asthma Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Biologics for Severe Asthma Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Biologics for Severe Asthma Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Biologics for Severe Asthma Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 67. India Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Biologics for Severe Asthma Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Biologics for Severe Asthma Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Biologics for Severe Asthma Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Biologics for Severe Asthma Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Biologics for Severe Asthma Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Biologics for Severe Asthma Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Biologics for Severe Asthma Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Biologics for Severe Asthma Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Biologics for Severe Asthma Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Biologics for Severe Asthma Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Biologics for Severe Asthma Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Biologics for Severe Asthma Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Biologics for Severe Asthma Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Biologics for Severe Asthma Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 88. Biologics for Severe Asthma Industry Chain Mapping
Figure 89. Regional Biologics for Severe Asthma Manufacturing Base Distribution (%)
Figure 90. Global Biologics for Severe Asthma Production Market Share by Region (2020-2031)
Figure 91. Biologics for Severe Asthma Production Process
Figure 92. Regional Biologics for Severe Asthma Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
Table 1. Global Biologics for Severe Asthma Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Biologics for Severe Asthma Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Biologics for Severe Asthma Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Biologics for Severe Asthma Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Biologics for Severe Asthma Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Biologics for Severe Asthma Sales by Region (2020-2025) & (K Units)
Table 8. Global Biologics for Severe Asthma Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Biologics for Severe Asthma Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Biologics for Severe Asthma Sales Share by Manufacturers (2020-2025)
Table 12. Global Biologics for Severe Asthma Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Biologics for Severe Asthma Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Biologics for Severe Asthma by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics for Severe Asthma as of 2024)
Table 16. Global Biologics for Severe Asthma Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Biologics for Severe Asthma Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Biologics for Severe Asthma Manufacturing Base and Headquarters
Table 19. Global Biologics for Severe Asthma Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Biologics for Severe Asthma Sales by Type (2020-2025) & (K Units)
Table 23. Global Biologics for Severe Asthma Sales by Type (2026-2031) & (K Units)
Table 24. Global Biologics for Severe Asthma Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Biologics for Severe Asthma Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Biologics for Severe Asthma ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Biologics for Severe Asthma Sales by Application (2020-2025) & (K Units)
Table 29. Global Biologics for Severe Asthma Sales by Application (2026-2031) & (K Units)
Table 30. Biologics for Severe Asthma High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Biologics for Severe Asthma Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Biologics for Severe Asthma Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Biologics for Severe Asthma ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Biologics for Severe Asthma Growth Accelerators and Market Barriers
Table 37. North America Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Biologics for Severe Asthma Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Biologics for Severe Asthma Growth Accelerators and Market Barriers
Table 40. Europe Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Biologics for Severe Asthma Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Biologics for Severe Asthma Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Biologics for Severe Asthma Growth Accelerators and Market Barriers
Table 45. Southeast Asia Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Biologics for Severe Asthma Investment Opportunities and Key Challenges
Table 47. Central and South America Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Biologics for Severe Asthma Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. AstraZeneca Corporation Information
Table 51. AstraZeneca Description and Major Businesses
Table 52. AstraZeneca Product Models, Descriptions and Specifications
Table 53. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. AstraZeneca Sales Value Proportion by Product in 2024
Table 55. AstraZeneca Sales Value Proportion by Application in 2024
Table 56. AstraZeneca Sales Value Proportion by Geographic Area in 2024
Table 57. AstraZeneca Biologics for Severe Asthma SWOT Analysis
Table 58. AstraZeneca Recent Developments
Table 59. Amgen Corporation Information
Table 60. Amgen Description and Major Businesses
Table 61. Amgen Product Models, Descriptions and Specifications
Table 62. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Amgen Sales Value Proportion by Product in 2024
Table 64. Amgen Sales Value Proportion by Application in 2024
Table 65. Amgen Sales Value Proportion by Geographic Area in 2024
Table 66. Amgen Biologics for Severe Asthma SWOT Analysis
Table 67. Amgen Recent Developments
Table 68. Roche Corporation Information
Table 69. Roche Description and Major Businesses
Table 70. Roche Product Models, Descriptions and Specifications
Table 71. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Roche Sales Value Proportion by Product in 2024
Table 73. Roche Sales Value Proportion by Application in 2024
Table 74. Roche Sales Value Proportion by Geographic Area in 2024
Table 75. Roche Biologics for Severe Asthma SWOT Analysis
Table 76. Roche Recent Developments
Table 77. Novartis Corporation Information
Table 78. Novartis Description and Major Businesses
Table 79. Novartis Product Models, Descriptions and Specifications
Table 80. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Novartis Sales Value Proportion by Product in 2024
Table 82. Novartis Sales Value Proportion by Application in 2024
Table 83. Novartis Sales Value Proportion by Geographic Area in 2024
Table 84. Novartis Biologics for Severe Asthma SWOT Analysis
Table 85. Novartis Recent Developments
Table 86. Sanofi Corporation Information
Table 87. Sanofi Description and Major Businesses
Table 88. Sanofi Product Models, Descriptions and Specifications
Table 89. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Sanofi Sales Value Proportion by Product in 2024
Table 91. Sanofi Sales Value Proportion by Application in 2024
Table 92. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 93. Sanofi Biologics for Severe Asthma SWOT Analysis
Table 94. Sanofi Recent Developments
Table 95. Regeneron Pharmaceuticals Corporation Information
Table 96. Regeneron Pharmaceuticals Description and Major Businesses
Table 97. Regeneron Pharmaceuticals Product Models, Descriptions and Specifications
Table 98. Regeneron Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Regeneron Pharmaceuticals Recent Developments
Table 100. GSK Corporation Information
Table 101. GSK Description and Major Businesses
Table 102. GSK Product Models, Descriptions and Specifications
Table 103. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. GSK Recent Developments
Table 105. Teva Pharmaceuticals Corporation Information
Table 106. Teva Pharmaceuticals Description and Major Businesses
Table 107. Teva Pharmaceuticals Product Models, Descriptions and Specifications
Table 108. Teva Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Teva Pharmaceuticals Recent Developments
Table 110. Key Raw Materials Distribution
Table 111. Raw Materials Key Suppliers
Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 113. Milestones in Production Technology Evolution
Table 114. Distributors List
Table 115. Market Trends and Market Evolution
Table 116. Market Drivers and Opportunities
Table 117. Market Challenges, Risks, and Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Biologics for Severe Asthma Product Picture
Figure 2. Global Biologics for Severe Asthma Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Omalizumab Product Picture
Figure 4. Benralizumab Product Picture
Figure 5. Dupirumab Product Picture
Figure 6. Mepolizumab Product Picture
Figure 7. Reslizumab Product Picture
Figure 8. Tezepelumab-ekko Product Picture
Figure 9. Global Biologics for Severe Asthma Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Other
Figure 13. Biologics for Severe Asthma Report Years Considered
Figure 14. Global Biologics for Severe Asthma Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 16. Global Biologics for Severe Asthma Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Biologics for Severe Asthma Revenue Market Share by Region (2020-2031)
Figure 18. Global Biologics for Severe Asthma Sales (2020-2031) & (K Units)
Figure 19. Global Biologics for Severe Asthma Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Biologics for Severe Asthma Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Biologics for Severe Asthma Sales Volume Market Share in 2024
Figure 22. Global Biologics for Severe Asthma Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Omalizumab Revenue Market Share by Manufacturer in 2024
Figure 25. Benralizumab Revenue Market Share by Manufacturer in 2024
Figure 26. Dupirumab Revenue Market Share by Manufacturer in 2024
Figure 27. Mepolizumab Revenue Market Share by Manufacturer in 2024
Figure 28. Reslizumab Revenue Market Share by Manufacturer in 2024
Figure 29. Tezepelumab-ekko Revenue Market Share by Manufacturer in 2024
Figure 30. Global Biologics for Severe Asthma Sales Market Share by Type (2020-2031)
Figure 31. Global Biologics for Severe Asthma Revenue Market Share by Type (2020-2031)
Figure 32. Global Biologics for Severe Asthma Sales Market Share by Application (2020-2031)
Figure 33. Global Biologics for Severe Asthma Revenue Market Share by Application (2020-2031)
Figure 34. North America Biologics for Severe Asthma Sales YoY (2020-2031) & (K Units)
Figure 35. North America Biologics for Severe Asthma Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Biologics for Severe Asthma Sales Revenue (US$ Million) in 2024
Figure 37. North America Biologics for Severe Asthma Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Biologics for Severe Asthma Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Biologics for Severe Asthma Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Biologics for Severe Asthma Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Biologics for Severe Asthma Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Biologics for Severe Asthma Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Biologics for Severe Asthma Sales Revenue (US$ Million) in 2024
Figure 47. Europe Biologics for Severe Asthma Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Biologics for Severe Asthma Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Biologics for Severe Asthma Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Biologics for Severe Asthma Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 52. France Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Biologics for Severe Asthma Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Biologics for Severe Asthma Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Biologics for Severe Asthma Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Biologics for Severe Asthma Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Biologics for Severe Asthma Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Biologics for Severe Asthma Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Biologics for Severe Asthma Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 67. India Biologics for Severe Asthma Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Biologics for Severe Asthma Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Biologics for Severe Asthma Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Biologics for Severe Asthma Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Biologics for Severe Asthma Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Biologics for Severe Asthma Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Biologics for Severe Asthma Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Biologics for Severe Asthma Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Biologics for Severe Asthma Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Biologics for Severe Asthma Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Biologics for Severe Asthma Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Biologics for Severe Asthma Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Biologics for Severe Asthma Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Biologics for Severe Asthma Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Biologics for Severe Asthma Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Biologics for Severe Asthma Revenue (2020-2025) & (US$ Million)
Figure 88. Biologics for Severe Asthma Industry Chain Mapping
Figure 89. Regional Biologics for Severe Asthma Manufacturing Base Distribution (%)
Figure 90. Global Biologics for Severe Asthma Production Market Share by Region (2020-2031)
Figure 91. Biologics for Severe Asthma Production Process
Figure 92. Regional Biologics for Severe Asthma Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232